Expert Interview
As the approval for FT218 continues to be delayed, we discuss its market potential with a prescriber of Xyrem/Xywav
Ticker(s): JAZZInstitution: University of Miami Sleep Disorders Center
- Board certified in Sleep Medicine and Neurology with Special Qualification in Child Neurology and the Medical Director of the Miami VA Healthcare system Sleep Disorders laboratory.
- Areas of expertise include sleep disorders following traumatic brain injury, sleep disturbances, headaches, sleep apnea, snoring, insomnia and narcolepsy.
- Clinicical research focus on sleep apnea and insomnia treatment adherence with an interest in the coexistence of sleep apnea and insomnia and how this complicates sleep disorders treatment.
Xywav currently has orphan drug exclusivity. Do you think FT218 will be considered clinically superior on the basis of safety or patient care as compared to Xywav? Do you think FT218 will be able to transcend Xywav's ODE ?
Added By: user5d2d4f30Generics entry in 2023.Characterize impact on branded adoption including FT218?
Added By: user5d2d4f30Do you think once nightly will meaningfully expand market of sodium?
Added By: user5d2d4f30Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
